KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Inventory (2016 - 2025)

Historic Inventory for Sarepta Therapeutics (SRPT) over the last 10 years, with Q3 2025 value amounting to $1.1 billion.

  • Sarepta Therapeutics' Inventory rose 9033.76% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 9033.76%. This contributed to the annual value of $750.0 million for FY2024, which is 13228.72% up from last year.
  • As of Q3 2025, Sarepta Therapeutics' Inventory stood at $1.1 billion, which was up 9033.76% from $994.0 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Inventory registered a high of $1.1 billion during Q3 2025, and its lowest value of $186.2 million during Q4 2021.
  • In the last 5 years, Sarepta Therapeutics' Inventory had a median value of $268.8 million in 2021 and averaged $421.1 million.
  • Its Inventory has fluctuated over the past 5 years, first plummeted by 2332.21% in 2022, then surged by 15203.65% in 2025.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Inventory stood at $186.2 million in 2021, then grew by 9.54% to $204.0 million in 2022, then skyrocketed by 58.29% to $322.9 million in 2023, then skyrocketed by 132.29% to $750.0 million in 2024, then skyrocketed by 43.63% to $1.1 billion in 2025.
  • Its Inventory was $1.1 billion in Q3 2025, compared to $994.0 million in Q2 2025 and $941.4 million in Q1 2025.